Münchener Rückversicherungs-Gesellschaft Aktiengesellschaft in München (OTCMKTS:MURGY) Stock Price Passes Above 50 Day Moving Average – Should You Sell?

Münchener Rückversicherungs-Gesellschaft Aktiengesellschaft in München (OTCMKTS:MURGY) shares crossed above its fifty day moving average during trading on Monday . The stock has a fifty day moving average of $10.40 and traded as high as $10.99. Münchener Rückversicherungs-Gesellschaft Aktiengesellschaft in München shares last traded at $10.92, with a volume of 226,164 shares changing hands.

Analyst Upgrades and Downgrades

A number of research firms recently commented on MURGY. Berenberg Bank cut Münchener Rückversicherungs-Gesellschaft Aktiengesellschaft in München from a “strong-buy” rating to a “hold” rating in a research report on Friday, October 25th. Jefferies Financial Group downgraded shares of Münchener Rückversicherungs-Gesellschaft Aktiengesellschaft in München from a “buy” rating to a “hold” rating in a report on Monday, October 21st.

Münchener Rückversicherungs-Gesellschaft Aktiengesellschaft in München Trading Up 1.0 %

The company has a market cap of $73.03 billion, a PE ratio of 13.06, a price-to-earnings-growth ratio of 1.88 and a beta of 1.02. The company has a current ratio of 1.12, a quick ratio of 1.12 and a debt-to-equity ratio of 0.20. The business has a 50 day simple moving average of $10.40 and a two-hundred day simple moving average of $10.26.

About Münchener Rückversicherungs-Gesellschaft Aktiengesellschaft in München

Münchener Rückversicherungs-Gesellschaft Aktiengesellschaft in München engages in the insurance and reinsurance businesses worldwide. It also offers life and health reinsurance solutions, such as digital underwriting and advanced analytics solutions, health insurance management system, financial market risks, financing, portfolio risk management, digitalized investment-linked solution, MIRA digital suite, MIRA POS, MIRApply insured and physician, claims risk adjustment, CLARA plus, data analytics, underwriting and claims, medical research, capital management, and health market.